Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Clin Pharmacol. 2014 Jul;7(4):415-21. doi: 10.1586/17512433.2014.919849. Epub 2014 May 22.

Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.

Author information

1
Section of Heart Failure/Transplant and Pulmonary Hypertension, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212-4772, USA.

Abstract

The endothelin pathway is a key pathway for the pathogenesis of pulmonary arterial hypertension (PAH). Antagonism of this pathway is recommended as initial therapy in low-risk patient with PAH to inhibit fibrosis, cell proliferation, and inflammation caused by endothelin. Prior to October 2013, ambrisentan, a selective ETA receptor antagonist and bosentan, a dual ETA/ETB antagonist, were the only currently available agents for PAH targeting the endothelin pathway. Based on the results of the SERAPHIN trial, macitentan (brand name OpsumitĀ®), a new ETA/ETB antagonist, has been US FDA approved to delay disease progression and reduce hospitalizations for PAH. SERAPHIN is the first ERA trial to use an event-driven strategy with a composite primary end point of morbidity or mortality. Previous trials have focused on short-term outcomes, such as improved 6-min walk distance and WHO functional class.

KEYWORDS:

drug development; endothelin; pharmacodynamics; pharmacokinetics; pulmonary arterial hypertension

PMID:
24851934
DOI:
10.1586/17512433.2014.919849
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center